New drug shows promise in taming epileptic brain signals
NCT ID NCT07125261
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This early-phase study tests whether BHV-7000, a drug that activates potassium channels, can reduce abnormal electrical activity in the brains of people with focal epilepsy who have an implanted RNS device. Five participants will take the drug for 4 weeks, and their brain recordings will be compared to a 90-day baseline and a 4-week withdrawal period. The goal is to see if the drug can calm seizure-related patterns without requiring long-term medication changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale Comprehensive Epilepsy Center
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.